Climb Bio Sees Unusually High Options Volume (NASDAQ:CLYM)

Posted by Geri Gentry on Aug 27th, 2026

Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) saw some unusual options trading on Wednesday. Stock traders bought 3,024 call options on the stock. This is an increase of approximately 740% compared to the typical volume of 360 call options.

Trending Headlines about Climb Bio

Here are the key news stories impacting Climb Bio this week:

Positive Sentiment: Unusually strong call-option activity provided a bullish trading signal: investors purchased 3,024 call options, roughly 740% above the average daily volume of 360 contracts. Options activity can indicate increased expectations for further share-price gains, although it does not guarantee a positive outcome.
Positive Sentiment: HC Wainwright raised its Climb Bio earnings estimates across multiple periods, including FY2026 EPS to a loss of $0.76 from a projected loss of $0.93, Q3 2026 EPS to a loss of $0.20 from $0.23, and Q4 EPS to a loss of $0.19 from $0.22. The firm also modestly improved its FY2027 forecast to a loss of $0.98 from $0.99. HC Wainwright maintained its Buy rating and $24 price target, above the stock’s recent trading level.
Positive Sentiment: Climb Bio’s Phase 2 trial in China is advancing, reinforcing the company’s clinical-development narrative and potentially supporting future value if results are favorable. Climb Bio Advances Phase 2 Trial in China
Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from the prior report. Because the figures appear inconsistent with an actively traded public company, the data offers little useful indication of short-selling pressure.
Negative Sentiment: The China Phase 2 progress is accompanied by a valuation concern: investors may already be pricing in substantial clinical success. That raises the risk of volatility or a pullback if upcoming trial updates fail to exceed expectations.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new position in Climb Bio in the second quarter valued at about $82,000. Braidwell LP grew its stake in Climb Bio by 102.6% during the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock worth $40,411,000 after buying an additional 1,569,352 shares in the last quarter. Wellington Management Group LLP bought a new position in Climb Bio in the 2nd quarter valued at about $1,262,000. Bank of America Corp DE bought a new position in Climb Bio in the 2nd quarter valued at about $335,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Climb Bio in the 2nd quarter valued at approximately $10,727,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Trading Down 9.9%

Shares of CLYM opened at $16.08 on Thursday. Climb Bio has a 12 month low of $1.54 and a 12 month high of $18.33. The firm’s 50 day moving average is $13.69 and its 200-day moving average is $10.37. The stock has a market capitalization of $923.64 million, a PE ratio of -19.37 and a beta of 0.08.

Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. Equities research analysts predict that Climb Bio will post -0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on CLYM. Chardan Capital started coverage on shares of Climb Bio in a research report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Friday, July 17th. Truist Financial increased their price objective on shares of Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Robert W. Baird set a $21.00 target price on shares of Climb Bio in a report on Wednesday, May 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Climb Bio in a research note on Wednesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $23.08.

Get Our Latest Stock Analysis on CLYM

Climb Bio Company Profile

(Get Free Report)

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.